Special Patient Populations

Special Patient Populations

Book Title

Neuraxial Therapeutics: A Comprehensive Guide

Description

As the use of intrathecal therapy has become more common in our armamentarium for the treatment of chronic pain, the indications for implantation have expanded to include new conditions and patient populations; however, the literature regarding these developing indications is sparse, consisting primarily of case reports and case series. As such, robust, long-term data are lacking. In this chapter, we review the management of intrathecal drug therapy in specific patient populations that require further attention. This includes patients with atypical pain syndromes, children, immunocompromised patients, and patients on blood thinning agents. In addition, we discuss treatment options for individuals with other implantable devices. Finally, we examine the treatment algorithm in the setting of cerebrospinal fluid leaks. Of note, while there are currently only three intrathecal agents approved for use by the Food and Drug Administration, morphine (an opioid), ziconotide (a non-opioid calcium channel antagonist), and baclofen (a GABAB receptor agonist), this chapter also reports on the use of investigational intrathecal therapies that are considered off-label.

First Page

775

Last Page

786

ISBN

9783031395574

Publication Date

1-2024

Publisher

Springer Nature

City

Switzerland

Keywords

intrathecal therapy

Disciplines

Neurosurgery

Special Patient Populations

Share

COinS